Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z.

Cancer Cell. 2010 Nov 16;18(5):423-35. doi: 10.1016/j.ccr.2010.10.025.

2.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.

Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.

PMID:
16683005
3.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.

Bull Cancer. 2007 Mar;94(3):259-66. Review. French.

4.

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.

Morrow PK, Zambrana F, Esteva FJ.

Breast Cancer Res. 2009;11(4):207. doi: 10.1186/bcr2324. Epub 2009 Jul 15. Review.

5.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
6.

HER-2-positive metastatic breast cancer: trastuzumab and beyond.

Metro G, Mottolese M, Fabi A.

Expert Opin Pharmacother. 2008 Oct;9(15):2583-601. doi: 10.1517/14656566.9.15.2583 . Review.

PMID:
18803447
7.

Trastuzumab: mechanisms of resistance and therapeutic opportunities.

Calabrich A, Fernandes Gdos S, Katz A.

Oncology (Williston Park). 2008 Oct;22(11):1250-8; discussion 1259, 1263. Review.

8.

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

Bedard PL, de Azambuja E, Cardoso F.

Curr Cancer Drug Targets. 2009 Mar;9(2):148-62. Review.

PMID:
19275756
9.

Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?

Arteaga CL.

J Clin Oncol. 2006 Aug 10;24(23):3722-5. Epub 2006 Jul 17. Review. No abstract available.

PMID:
16847283
10.

[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].

Dank M.

Orv Hetil. 2001 Nov 18;142(46):2563-8. Review. Hungarian.

PMID:
11770175
11.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA Jr.

Clin Breast Cancer. 2002 May;3 Suppl 1:12-6. Review.

PMID:
12057039
12.

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.

Mukohara T.

Cancer Sci. 2011 Jan;102(1):1-8. doi: 10.1111/j.1349-7006.2010.01711.x. Epub 2010 Sep 6. Review.

13.

Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

Esteva FJ, Pusztai L.

Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.

14.

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

Garnock-Jones KP, Keating GM, Scott LJ.

Drugs. 2010;70(2):215-39. doi: 10.2165/11203700-000000000-00000. Review. Erratum in: Drugs. 2011 Aug;71(12):1578.

PMID:
20108993

Supplemental Content

Support Center